piracetam has been researched along with Abnormalities, Drug-Induced in 10 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 7.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 3.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "The current evidence suggests that the overall risk of major malformation after first trimester exposure to Levetiracetam is within the population baseline risk of 1-3%, with no apparent adverse effects on long term child development." | 2.50 | The fetal safety of Levetiracetam: a systematic review. ( Chaudhry, SA; Jong, G; Koren, G, 2014) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Levetiracetam is a Pregnancy Category C drug." | 2.41 | Safety profile of levetiracetam. ( Harden, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhry, SA | 1 |
| Jong, G | 1 |
| Koren, G | 1 |
| Vajda, FJ | 2 |
| O'Brien, TJ | 3 |
| Lander, CM | 3 |
| Graham, J | 3 |
| Eadie, MJ | 2 |
| Vajda, FJE | 1 |
| Iniesta, I | 1 |
| Roten, A | 1 |
| Eadie, M | 1 |
| Mawhinney, E | 1 |
| Craig, J | 2 |
| Morrow, J | 2 |
| Russell, A | 2 |
| Smithson, WH | 1 |
| Parsons, L | 2 |
| Morrison, PJ | 2 |
| Liggan, B | 1 |
| Irwin, B | 2 |
| Delanty, N | 1 |
| Hunt, SJ | 1 |
| Long, L | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Hunt, S | 1 |
| Guthrie, E | 1 |
| Robertson, I | 1 |
| Waddell, R | 1 |
| Harden, C | 1 |
4 reviews available for piracetam and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The fetal safety of Levetiracetam: a systematic review.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Fetal Diseases; Fetus; Humans; Leveti | 2014 |
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
Safety profile of levetiracetam.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Central Nervous System Diseases; Controlled Clinical T | 2001 |
6 other studies available for piracetam and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Teratogenicity of the newer antiepileptic drugs--the Australian experience.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Administration Schedule; Female; Fruct | 2012 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Levetiracetam monotherapy during pregnancy: a case series.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Levetiracet | 2003 |
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Infant, | 2006 |